Weekly Isotretinoin Therapy (WIT) Study: A Potential Alternative for the Treatment of Moderate Acne Vulgaris
Main Article Content
Keywords
Acne, Isotretinoin, Moderate acne, Weekly isotretinoin
Abstract
Background: Treatment options for moderate acne remain limited.
Methods: We evaluated the efficacy of once-weekly dosed isotretinoin for moderate acne. Nineteen participants took isotretinoin dosed at 1-1.5 mg/kg/week for four months. Patient clinical improvement, quality of life, and adverse effects were measured at baseline and at monthly follow-up visits. Laboratory monitoring was performed at baseline and after two months.
Results: Ninety-five percent of patients (18/19) had improvement in their acne. The majority (68%) went from a baseline of moderate acne (score 3) to either clear (score 0) or almost clear (score 1) by the end of four months. There were no major lab abnormalities or adverse events. Eighty-nine percent of patients (17/19) reported improvement in their quality of life.
Conclusion: Once weekly isotretinoin may be an additional treatment option for patients with moderate acne.
References
2. Rademaker M, Wishart JM, Birchall NM. Isotretinoin 5 mg daily for low-grade adult acne – a placebo-controlled, randomized double-blind study. JEADV. 2014;28:747–54.
3. Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, Hong CK. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011;164(6):1369. Epub 2011 May 17.
4. Kaymak Y, Ilter N. The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol. 2006;20:1256–60
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.